Cardioprotection thread, page-712

Upcoming CPACS trial is allcomers cardio protect anti-cancer. For labelling purposes this would have to result in statistically significant results in both cardio protect and anti-cancer. Otherwise labelling will be akin to Dexrazoxane (merely cardio protection), which wouldn't maximise value. Or if P2 results in a narrow CPACS target then gives the option to label under single indication.

To top this off its not just anti-cancer in breast cancer but also a basket trial of cancers. So what? If you missed it the bigger play is also FTO inhibition proof-of-concept. To correlate anti-cancer to m6A will get pharma excited so perhaps DrT hasn't yet conceded Cardio protect as being the bigger elephant, happy to be corrected.

The way i see it is, Cardio protect will open the door and FTO will seal the deal. Race could have just undertaken a Breast cancer CPACS trial, but why not? Race would have Oncolines FTO data to correlate anti-cancer effect in-vitro results of Dox+Bisantrene. If not, Race would effectively be adding in a secondary endpoint as a guess, not sure that is how clinical trials are designed and tested by scientists?

@Anydaynow the trials in south korea and hong kong are not by chance. Its a geographical license play starting off at the small end then China (big end) before US (end game / exit). My thoughts only - DYOR. Great questions, but just a reminder Hotcopper isnt a Q&A you need to do your own research and come to your own conclusions, the answers are there.